RANDOMIZED STUDY OF DOXORUBICIN PLUS CISPLATIN VS CIRCADIAN-TIMED DOXORUBICIN

患有III、IV期或复发性子宫内膜癌的女性，既往未 接受化疗的患者有资格参加本研究。 本研究的目的是确定昼夜节律定时的阿霉素- 顺铂化疗显著改善了 客观缓解、无进展间期持续时间和 与标准阿霉素-顺铂相比的生存期 化疗，并确定是否有任何显着差异， 阿霉素-顺铂的昼夜节律定时递送之间的毒性， 化疗与阿霉素-顺铂标准给药的比较 化疗 本研究是一项随机化研究， 将对两种治疗中的每一种进行相等的概率 在所有GOG内平衡分配方案顺序的方案 参与这项研究的机构。我估计 20个病人。

Women with stage III, IV or recurrent endometrial carcinoma previously not treated with chemotherapy are eligible for the study. The aims of this study are to determine if circadian-timed doxorubicin- cisplatin chemotherapy offers significant improvement in the frequency of objective response, the duration of progression-free interval and the length of survival as compared to standard doxorubicin-cisplatin chemotherapy and to determine if there are any significant differences in toxicity between circadian-timed delivery of doxorubicin-cisplatin, chemotherapy versus standard delivery of doxorubicin-cisplatin chemotherapy. This study is a randomized study and randomization with equal probabilities will be carried out to each of the two treatment regimens balancing the sequence of assigned regimens within all GOG institutions participating in this study. I would estimate the accrual of twenty patients from this institution.